Endothelial dysfunction in acute renal ischemia

$348,718R01FY2007DKNIH

New York Medical College, Valhalla NY

Investigators

Linked publications & trials

Paper 29726981 Paper 28476555 Paper 28297566 Paper 28167639 Paper 27524235 Paper 27451101 Paper 27165830 Paper 26948035 Paper 26683662 Paper 25947337 Paper 25936481 Paper 25834071 Paper 25754206 Paper 25535303 Paper 25217265 Paper 24940804 Paper 24727495 Paper 24136919 Paper 23776484 Paper 23761107 Paper 23685680 Paper 23507925 Paper 23349311 Paper 23088293 Paper 22761782 Paper 22759395 Paper 22617768 Paper 22234173 Paper 22189943 Paper 22160777 Paper 21841835 Paper 21775481 Paper 21705809 Paper 21136903 Paper 20592859 Paper 20571092 Paper 20558574 Paper 20482449 Paper 20410213 Paper 20395371 Paper 20237239 Paper 20200095 Paper 20167859 Paper 19906947 Paper 19556996 Paper 19444962 Paper 19398655 Paper 19318942 Paper 19147816 Paper 19095954 Paper 18715993 Paper 18596729 Paper 18588980 Paper 18587721 Paper 18003856 Paper 17881464 Paper 17625117 Paper 17444281 Paper 17409313 Paper 17331118 Paper 17290297 Paper 16963618 Paper 16932479 Paper 16603702 Paper 16487748 Paper 16478972 Paper 16361365 Paper 16325173 Paper 16106036 Paper 15579528 Paper 15252771 Paper 15198930 Paper 15016631 Paper 15010359 Paper 14761967 Paper 12845232 Paper 12411749 Paper 12384491 Paper 12089067 Paper 12060581 Paper 12003820 Paper 11997332 Paper 11997331 Paper 11937763 Paper 11877351 Paper 11849438 Paper 11592952 Paper 11316862 Paper 11249846 Paper 11230367 Paper 11157677 Paper 10997917 Paper 10691777

Abstract

four pages for each - )) ...................... 9 Resources ........................................................................................................................................... 22 Research Plan 23 Introduction to RevisedApplication (Not to exceed 3 pages) .................................................................................................................. Introduction to SupplementalApplication (Not to exceed one page) ....................................................................................................... 23 A. Specific Aims ............................................................................ _'1" ......................................................................................... J"" 24 B. Backgroundand Significance.................................................... """t"....................................................................................... t'" 26 C. PreliminaryStudies/ProgressReport/ _;=,.(Items A-D: not to exceed 25 pages*) .._ Phase I ProgressReport (SBIRISTTR Phase II ONLY) I SBIFUSTTRPhase/: Items A.D limitedto 15 pages. I D, Research Designand Methods................................................. _ .......................................................................................... 34 E. Human Subjects........................................................................................................................................................................... 46 Protectionof Human Subjects(Required if Item 4 on the Face Page is marked "Yes") Inclusionof Women (Required if Item4 on the Face Page is marked"Yes") .......................................................................... Inclusion of Minorities(Required ir Item 4 on the Face Page is marked "Yes") ........................................................................ Inclusionof Children(Required if Item 4 on the Face Page is marked =Yes").......................................................................... Data and SafetyMonitoringPlan (Required if Item4 on the Face Page is marked "Yes" anda Phase I, I1,or Ill clinical tdalis proposed................................................................................................................................................................. F. VertebrateAnimals....................................................................................................................................................................... 46 G. LiteratureCited............................................................................................................................................................................. 46 H. Consortium/ContractuaAl rrangements ........................................................................................................................................ 51 I. Consultants.................................................................................................................................................................................. 51 J. Product Development Plan (SBIR/STTR Phase II and Fast-Track ONLY) .................................................................................. Checklist ............................................................................................................................................. 52 Check if Appendix (Five collatedsets. No page numbetfngnecessary forAppendix.) Appendixis Included AppendicesNO T PERMITTED for Phase I SB/R/STTR unlessspecilfcaliysolicited. Number of publicationsand manuscriptsacceptedfor publication (not to exceed 10) 10 Other items (list): 1. Color illustrations from the grant application 2. Movies - intravital videomicroscopy supplement

View original record on NIH RePORTER →